Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : GLAXF save search
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
Published: 2023-02-10 (Crawled : 08:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.43%
H: 0.66%
C: 0.66%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.07%
H: 0.06%
C: -0.55%
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: 0.04%
H: 1.27%
C: -0.62%
treatment fda grants approval cancer
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: -1.87%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
fda approval hiv order
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.09%
H: 0.8%
C: 0.63%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.45%
H: 0.53%
C: 0.42%
treatment fda health fda approval thc approval hiv
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.73%
H: 0.13%
C: -0.44%
new drug fda drug hiv application granted grant
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.